Prostate cancer is the most common non-cutaneous malignant lesion in males over 70 years of age. Diagnosis in advanced stages of the disease is not exceptional, through metastatic lesions as debut. The most characteristic of these lesions are osseous with osteoblastic behavior, uncommon in maxillary bones. On the other hand, Paget's disease is a chronic metabolic disorder attributed to osteoclast dysfunction. At the craniofacial level, the characteristic affectation is an increase in size, a "cotton flakes" pattern or circumscribed osteoporosis. The fact that this is only located in the mandible is exceptional. A case of Paget's disease of the right hemi-mandible bone is presented in which a metastasis is developed due to prostatic adenocarcinoma.

Objective: Retrospective descriptive study of 21 oral soft tissue and/or maxillary bone metastatic cases.Materials and methods: Hospital records of our own department are reviewed for a 12-year period. Lymphoproliferative diseases, skin metastases, salivary glands, other craniofacial bones and cervical lymph-nodes are excluded. Epidemiologic, personal health, clinical, treatment and follow-up data are recollected and analysed in frequency statistics. Results: Male:Female ratio is 1.3:1, year-old range 52-82 and ethnic group 100 % white-caucasian. 19.0 % have carcinogenic occupational exposure, 52.4 % tobacco abuse, 61.9 % some kind of alcohol use, 57.1 % cardiovascular risk, 19.0 % cardiologic records, 28.6 % pulmonary, 19.0 % gastrointestinal, 19.0 % endocrine, 14.3 % genitourinary, 9.5 % other primary malignancy and 23.8% a first-degree relative with a neoplasm. 33.3 % patients have taken osteonecrosisrelated drugs or received craniofacial radiotherapy.Metastasis is the debut in 7 patients while it corresponds to infirmity progression in 14. The chief reason for consultation is a mass. 8 lesions affect soft tissue and 13 the bone. 81.0 % have epithelial neoplasm lineages. The organ of origin is: 23.8 % lung, 23.8 breast, 23.8 % kidney, 9.5 % skin, 9.5 % soft parts, 4.8 % prostate and 4.8 % thyroid. 100 % have other location metastases. 14.3 % patients undergo surgery, 38.1 % receive radiotherapy, 47.6 % chemo-or targeted therapy, and 28.6 % symptomatic treatment. After a 1-124 months range of followup, 17 patients die and 4 are alive. 1130-0558/